<DOC>
	<DOC>NCT02586857</DOC>
	<brief_summary>A Phase 1b/2, multicenter, open-label study designed to evaluate the efficacy and safety of ACP-196 in subjects with recurrent GBM who have progressed after 1 or 2 prior systemic treatment regimens.</brief_summary>
	<brief_title>A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Histologically confirmed GBM at first or second recurrence after concurrent or adjuvant chemotherapy or radiotherapy (must have received temozolomide). Radiographic demonstration of disease progression by MRI following prior therapy. ECOG performance status ≤ 2. Life expectancy ≥ 12 weeks. Completion of all prior anticancer therapy before first ACP196 dose. Three or more prior lines of systemic therapy for GBM. Significant cardiovascular disease. Evidence of bleeding diathesis or coagulopathy. Requires urgent palliative intervention for primary disease. History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug. Breastfeeding or pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
</DOC>